Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension

Regulatory Peptides

Volumn 151, Issue 1-3, 2008, Pages 48-53

  Vizza, Carmine Dario ^a   Letizia, Claudio ^b   Petramala, Luigi ^b   Badagliacca, Roberto ^a   Poscia, Roberto ^a   Zepponi, Enrico ^c   Crescenzi, Eleonora ^a   Nona, Alfred ^a   Benedetti, Giulia ^a   Ferrante, Fabio ^a   Sciomer, Susanna ^a   Fedele, Francesco ^a  

^a Dept Cardiovascular and Respiratory Science ^*  (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Rieti Hospital   (Italy)

Author keywords

Bosentan; Brain natriuretic peptide; Cardiovascular disease; Endothelin 1; Pulmonary arterial hypertension

Indexed keywords

AMIODARONE; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; ENDOTHELIN 1; FUROSEMIDE; PREDNISONE; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LUNG HEMODYNAMICS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SIDE EFFECT;

ADULT; ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; TIME FACTORS;

EID: 56249104093     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.08.002     Document Type: Article

References (31)

1. In: Rich S. (Ed). Primary pulmonary hypertension: executive summary from the world symposium (1998), World Health Organization, Geneva
2. Masaki T., Yanagisawa M., and Goto K. Physiology and pharmacology of endothelins. Med Res Rev 12 (1992) 391-421
3. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
4. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
5. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26 (1995) 1581-1585
6. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569
7. Langleben D., Barst R.J., Badesch D., et al. Continuous infusion of epoprostenol improves the net bilance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 99 (1999) 3266-3271
8. Wilkens H., Bauer M., Forestier N., et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation 107 (2003) 1732-1739
9. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 358 (2001) 1119-1123
10. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
11. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
12. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
13. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
14. Guyatt G.H., Thompson P.J., Berman L.B., et al. How should we measure function in patients with chronic heart and lung disease?. J Chronic Dis 38 (1985) 517-524
15. Letizia C., Cerci S., De Ciocchis A., et al. Plasma endothelin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressure test. J Hum Hypertension 9 (1995) 903-907
16. Winer B.J. Statistical principles in experimental design (1971), McGraw-Hill, New York
17. Rondelet B., Kerbaul F., Motte S., et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107 (2003) 1329-1335
18. Yoshibayashi M., Nishioka K., Nakao K., et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84 (1991) 2280-2285
19. Morelli S., Ferri C., Polettini E., Bellini C., Gualdi G.F., Pittoni V., Valesini G., and Santucci A. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99 (1995) 255-260
20. Langleben D., Dupuis J., Langleben I., et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 129 (2006) 689-695
21. Dupuis J., Stewart D.J., Cernacek P., et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94 (1996) 1578-1584
22. Cacoub P., Dorent R., Nataf P., et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc. Res 33 (1997) 196-200
23. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
24. Leuchte H.H., El Nounou M., Tuerpe J.C., et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 131 (2007) 402-409
25. Nagaya N., Ando M., Oya H., et al. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 74 (2002) 180-184
26. Hiramoto Y., Shioyama W., Kuroda T., et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 71 (2007) 367-369
27. Sutsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 (1998) 2262-2268
28. Dingemanse J., and van Giersbergen P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43 (2004) 1089-1115
29. Givertz M.M., Colucci W.S., LeJemtel T.H., Gottlieb S.S., Hare J.M., Slawsky M.T., Leier C.V., Loh E., Nicklas J.M., and Lewis B.E. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 27 101 (2000) 2922-2927
30. Leslie S.J., Spratt J.C.S., McKee S.P., Strachan F.E., Newby D.E., Northridge D.B., Denvir M.A., and Webb D.J. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart 91 (2005) 914-919
31. Grewal J., McKelvie R., Lonn E., Tait P., Carlsson J., Gianni M., Jarnert C., and Persson H. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail 10 (2008) 252-259